Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Hitting Home Runs & Grand Slams, Not Loud Outs
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- RTI: When Will We Finally See a Pullback?
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 8.21% |
| MAXWELL TECH | MXWL | 5.00% |
| A M R CP | AAMRQ | 3.78% |
| ALLIANCE FIB | AFOP | 3.02% |
| SYNAPTICS IN | SYNA | 2.77% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
On Jan 30, we upgraded drugstore chain retailer, Rite Aid Corporation ( RAD - Analyst Report ) to Outperform based on the company’s impressive performance during the third-quarter of fiscal 2013 and an upbeat guidance.
Why the Upgrade?
Rite Aid reported earnings of 7 cents a share that fared significantly better than both the year-ago quarter’s loss of 6 cents as well as the Zacks Consensus Estimate of a loss of 4 cents. Results also improved sequentially as the company swung back to profit, reflecting rise in front-end sales, favorable script trends and introduction of new generic medications.
Rite Aid's gross margin expanded 250 basis points to 29.0% during the quarter, while adjusted EBITDA margin expanded 120 basis points to 4.7%. Consequently, the company now expects bottom-line results to come in the range of a loss per share of 5 cents to earnings per share of 3 cents, up from its previous guidance of loss per share in the range of 9 cents – 23 cents.
The strong positive bias on this Zacks Rank #1 (Strong Buy) company has been fuelled by several strategic steps taken to boost its long-term profitability. Rite Aid is focusing on expanding its pharmacy and clinical services and striving to abridge costs.
The company’s Wellness+ customer loyalty program has been successful in luring customers as the Wellness+ members now account for 76% of front end sales compared with 72% in the year-ago quarter. On the cost front, the company is focusing on generating cost savings through centralized indirect procurement of drugs and reduction in supply chain costs.
Going forward, Rite Aid remains focused on expanding its portfolio of generic medications, which in turn will facilitate the company in enhancing margins.
Other Stocks to Consider
Besides Rite Aid, other stocks in the healthcare industry that are worthy of a consideration include AmerisourceBergen Corporation ( ABC - Analyst Report ) , GNC Holdings Inc. ( GNC - Snapshot Report ) and Herbalife Ltd. ( HLF - Snapshot Report ) all carrying a Zacks Rank #2 (Buy) and are expected to continue with their upbeat performances.
Read the full reports :
Analyst Report on RAD
Snapshot Report on GNC
Analyst Report on ABC
Snapshot Report on HLF